MX2011013459A - Terapia de peptido para incrementar los niveles de plaquetas. - Google Patents

Terapia de peptido para incrementar los niveles de plaquetas.

Info

Publication number
MX2011013459A
MX2011013459A MX2011013459A MX2011013459A MX2011013459A MX 2011013459 A MX2011013459 A MX 2011013459A MX 2011013459 A MX2011013459 A MX 2011013459A MX 2011013459 A MX2011013459 A MX 2011013459A MX 2011013459 A MX2011013459 A MX 2011013459A
Authority
MX
Mexico
Prior art keywords
platelet levels
peptide therapy
increasing platelet
compositions
increasing
Prior art date
Application number
MX2011013459A
Other languages
English (en)
Inventor
Michal Abraham
Amnon Peled
Orly Eizenberg
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of MX2011013459A publication Critical patent/MX2011013459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se dirige a usos terapéuticos novedosos de péptidos análogos T-140 y composiciones que los comprenden. Específicamente, la invención se relaciona a composiciones y métodos para proporcionar niveles de plaquetas mejorados, útiles en el tratamiento y prevención de trombocitopenia, para controlar el sangrado y para inducir o modular la hemostasis.
MX2011013459A 2009-06-14 2010-06-13 Terapia de peptido para incrementar los niveles de plaquetas. MX2011013459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18685709P 2009-06-14 2009-06-14
PCT/IL2010/000466 WO2010146578A2 (en) 2009-06-14 2010-06-13 Peptide therapy for increasing platelet levels

Publications (1)

Publication Number Publication Date
MX2011013459A true MX2011013459A (es) 2012-05-08

Family

ID=43356827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013459A MX2011013459A (es) 2009-06-14 2010-06-13 Terapia de peptido para incrementar los niveles de plaquetas.

Country Status (11)

Country Link
US (1) US9427456B2 (es)
EP (1) EP2442822B1 (es)
JP (1) JP5715622B2 (es)
KR (1) KR101719339B1 (es)
CN (1) CN102481332A (es)
BR (1) BRPI1009663A2 (es)
CA (1) CA2765345C (es)
ES (1) ES2462517T3 (es)
IL (1) IL216912A (es)
MX (1) MX2011013459A (es)
WO (1) WO2010146578A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
CA2673484A1 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
US20130303460A1 (en) 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
WO2014089478A1 (en) * 2012-12-07 2014-06-12 University Of Tennessee Research Foundation Methods of numerical analysis for platelet disorders and computer-readable media and systems for performing the same
EP3142657B1 (en) 2014-05-15 2019-09-11 Enzychem Lifesciences Corporation Methods for treating neutropenia
JP6547274B2 (ja) 2014-10-20 2019-07-24 株式会社デンソー 粒子状物質検出センサ
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
MX2021008942A (es) * 2019-01-25 2021-08-24 Janssen Pharmaceutica Nv Metodos para mitigar efectos toxicos vesicantes y gas caustico.
IL296338A (en) * 2020-03-11 2022-11-01 Biolinerx Ltd cxcr4 inhibitor for the treatment of acute respiratory syndrome and viral infections
CA3205663A1 (en) 2020-12-30 2022-07-07 Biolinerx Ltd. Process for manufacturing peptide
CN118027155A (zh) * 2024-04-15 2024-05-14 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0396158A1 (en) 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0220520B1 (en) 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
DE3777845D1 (de) 1986-01-22 1992-05-07 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
CA1297004C (en) 1986-01-22 1992-03-10 Masahiko Tamura Pharmaceutical agent for promoting the recovery of hemopoietic capacity
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (de) 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
CA1339071C (en) 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
DE69416824T2 (de) 1993-10-14 1999-07-08 Seikagaku Kogyo Co Ltd Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
EP0983082A1 (en) 1997-05-21 2000-03-08 Genentech, Inc. Novel administration of thrombopoietin
WO1998052465A1 (en) 1997-05-23 1998-11-26 Transurgical, Inc. Mri-guided therapeutic unit and methods
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
EE200100203A (et) 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
EP1124614A1 (de) 1998-10-27 2001-08-22 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
DE60042921D1 (de) 1999-03-29 2009-10-22 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
CA2389979C (en) 1999-11-24 2011-08-16 Schering Corporation Methods of inhibiting metastasis
WO2001064716A1 (fr) 2000-03-03 2001-09-07 Nobutaka Fujii Composes antiviraux
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP1323730B1 (en) 2000-09-05 2010-04-21 Biokine Therapeutics Ltd. Novel polypeptides and anti-hiv drugs containing the same
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (ja) 2001-02-16 2003-02-10 サンケン電気株式会社 スイッチング電源装置
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
ES2403932T3 (es) * 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
JP4666256B2 (ja) 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) * 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
CA2533753C (en) 2004-03-19 2012-10-16 Morinaga Milk Industry Co., Ltd. Drug for cancer therapy
AU2005272653A1 (en) 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
AU2006280945A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
CN101573441A (zh) 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 非常小的胚胎样（vsel）干细胞及分离和利用其的方法
US20080038231A1 (en) 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
AR063470A1 (es) 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
US7968098B2 (en) 2006-08-04 2011-06-28 Kurume University HLA-A24-binding KIF-derived peptide
CA2673484A1 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
KR20120046163A (ko) 2009-06-15 2012-05-09 바이오카인 테라퓨틱스 리미티드 자가면역, 염증 및 암의 과정을 저해할 수 있는 신규한 케모카인 결합 폴리펩타이드류
US20120082687A1 (en) 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
US20130303460A1 (en) 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
AU2014240733B2 (en) 2013-03-24 2018-11-22 Biolinerx Ltd. Methods of treating myeloid leukemia
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
EP3062809B1 (en) 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Also Published As

Publication number Publication date
US20120094907A1 (en) 2012-04-19
WO2010146578A3 (en) 2011-02-10
KR101719339B1 (ko) 2017-03-23
EP2442822A4 (en) 2013-01-23
CN102481332A (zh) 2012-05-30
IL216912A0 (en) 2012-02-29
EP2442822A2 (en) 2012-04-25
CA2765345A1 (en) 2010-12-23
JP5715622B2 (ja) 2015-05-07
KR20120037463A (ko) 2012-04-19
JP2012530130A (ja) 2012-11-29
ES2462517T3 (es) 2014-05-23
US9427456B2 (en) 2016-08-30
CA2765345C (en) 2016-06-21
BRPI1009663A2 (pt) 2016-10-11
WO2010146578A2 (en) 2010-12-23
EP2442822B1 (en) 2014-03-05
IL216912A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MX2011013459A (es) Terapia de peptido para incrementar los niveles de plaquetas.
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
MX2012009748A (es) USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
PH12015501806B1 (en) Novel benzopyran kinase modulators
MX2009013970A (es) Gel de fibrina para la liberacion controlada del factor de crecimiento derivado de plaqueta (pdgf) y sus usos.
IN2012DN00624A (es)
EA201170349A1 (ru) Модуляторы mif
ZA201108305B (en) Novel p2x7r antagonists and their use
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
WO2012082950A3 (en) Chimeric fibronectin matrix mimetics and uses thereof
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
MX2011009277A (es) Composicion de leucocito activada.
BRPI1006076B8 (pt) composições farmacêuticas
WO2006130718A3 (en) Synthetic peptide inhibitors of thrombin

Legal Events

Date Code Title Description
FG Grant or registration